Inhibrx Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Inhibrx Biosciences

13/08/2025 22:01

Inhibrx Biosciences Inc INBX.OQ reported a quarterly adjusted loss of $1.85​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $125.48.  The mean expectation of two analysts for the quarter was for a loss of $2.76 per share. Wall Street expected results to range from $-2.92 to $-2.60 per share.

Revenue rose 1,200% to $1.30 million from a year ago; analysts expected zero.

Inhibrx Biosciences Inc's reported EPS for the quarter was a loss of $1.85​.

The company reported a quarterly loss of $28.65 million.

Inhibrx Biosciences Inc shares had risen by 53.6% this quarter and gained 42.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 8.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

Wall Street's median 12-month price target for Inhibrx Biosciences Inc is $12.00, about 82.7% below its last closing price of $21.92

This summary was machine generated from LSEG data August 13 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-2.76
-1.85
Beat
Mar. 31 2025
-2.84
-2.80
Beat
Dec. 31 2024
-2.89
-3.09
Missed
Sep. 30 2024
-3.38
-2.84
Beat